醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

Archive > Volume 15 Issue 4 > 2023,15(4):476-484. DOI:https://doi.org/10.1016/j.chmed.2023.09.002 Prev Next

以臨床價(jià)值為導(dǎo)向的中醫(yī)藥治療優(yōu)勢病種傳承創(chuàng)新研究新范式

Reviews

Clinical value-oriented research paradigm about inheritance and innovation development of TCM dominant diseases

  • Article
  • Figures
  • Metrics
  • Preview PDF
  • Reference
  • Related
  • Cited by
  • Materials
    摘要:
    現(xiàn)代醫(yī)學(xué)在保障人民生命健康取方面成就斐然，然而人們越來越發(fā)現(xiàn)面對復(fù)雜疾病，選擇性地針對單一靶點(diǎn)往往很難產(chǎn)生綜合性的康復(fù)效果，并且容易產(chǎn)生耐藥性、毒副作用等。傳統(tǒng)中醫(yī)藥具有悠久的臨床應(yīng)用歷史，并證實(shí)其在心腦血管疾病、消化系統(tǒng)疾病、皮膚病、風(fēng)濕免疫疾病、腫瘤輔助治療等復(fù)雜疾病的治療方面臨床價(jià)值優(yōu)勢明顯。然而其現(xiàn)代研究相對滯后，面對老齡化社會及現(xiàn)代疾病譜特征，以傳統(tǒng)知識驅(qū)動型的研究范式似乎陷入了瓶頸難以取得更大突破。圍繞新時(shí)代中醫(yī)藥發(fā)展的關(guān)鍵問題，以臨床價(jià)值為導(dǎo)向的中醫(yī)藥傳承創(chuàng)新發(fā)展是當(dāng)前推進(jìn)中醫(yī)藥現(xiàn)代化發(fā)展的重要任務(wù)，中醫(yī)藥優(yōu)勢病種是中醫(yī)藥傳承創(chuàng)新發(fā)展的重要抓手，近年得到了中醫(yī)藥學(xué)術(shù)界和國家有關(guān)管理部門的高度重視，制定了一系列基于中醫(yī) 藥優(yōu)勢病種的管理政策，針對中醫(yī)藥優(yōu)勢病種的遴選與評價(jià)方法、臨床療效特色總結(jié)、現(xiàn)代科學(xué)內(nèi)涵闡釋策略等開展了大量探索性研究，初步形成了以臨床價(jià)值為導(dǎo)向的中醫(yī)藥優(yōu)勢病種傳承創(chuàng)新科研范式，其特征主要體現(xiàn)在以強(qiáng)有力的政策支持為保障，以系統(tǒng)規(guī)范的遴選與評價(jià)方法為推手，以科學(xué)有效的內(nèi)涵機(jī)制研究為拓展，以及行之有效的臨床指導(dǎo)規(guī)范及原則為轉(zhuǎn)化，對促進(jìn)中醫(yī)藥事業(yè)與產(chǎn)業(yè)高質(zhì)量發(fā)展具有重要價(jià)值。本文從近年中醫(yī)藥優(yōu)勢病種的主要政策支持、遴選和評價(jià)方法、療效特點(diǎn)分析以及現(xiàn)代科學(xué)內(nèi)涵研究策略等幾方面對中醫(yī)藥優(yōu)勢病種研究進(jìn)行了全面梳理，以期為中醫(yī)藥優(yōu)勢病種研究的健康良性發(fā)展提供一定參考。

    Abstract:
    Modern medicine has made remarkable achievements in safeguarding people’s life and health, however, it is increasingly found that in the face of complex diseases, selective targeting single target is often difficult to produce a comprehensive rehabilitation effect, and is prone to induce drug resistance, toxic side effects. Traditional Chinese medicine (TCM) has a long history of clinical application, and its clinical value in the treatment of complex diseases such as cardiovascular and cerebrovascular diseases, digestive diseases, skin diseases, rheumatism and immunity diseases, and adjuvant treatment of tumors has been proven to have obvious advantages. However, its modern research is relatively lagging behind, and in the face of the aging society and the characteristics of the modern disease spectrum, the traditional knowledge-driven research paradigm seems to be stuck in a bottleneck and difficult to make greater breakthroughs. Focusing on the key issues of TCM development in the new era, the clinical value-oriented strategy becomes to be a new research paradigm of TCM inheritance and innovation development, and dominant diseases would be the focus of the TCM inheritance and innovation development, which has been highly valued in recent years by the TCM academia and the relevant national management departments. Based on the clinical value, a series of policies are formulated for the selection and evaluation of the TCM dominant diseases (TCMDD), and exploratory researches about the clinical efficacy characteristics, the modern scientific connotation interpretation were carried out. The clinical value-oriented research paradigm of TCMDD inheritance and innovation development has been initially formed, which is characterized by strong policy support as the guarantee, systematic and standardized selection and evaluation methods as the driving force, scientific and effective research on internal mechanisms as the expansion, and effective clinical guidelines and principles as the transformation, which is of great value in promoting the high-quality development of the industries and undertaking of TCM. In this paper, the main policy support, selection and evaluation methods, therapeutic effect characterization, and modern scientific connotation research strategies of TCMDD in recent years have been comprehensively sorted out, with a view to providing the healthy and benign development of the research on TCMDD.

    關(guān)鍵詞:
    臨床價(jià)值;傳承創(chuàng)新;研究范式;中醫(yī)藥優(yōu)勢病種

    Keywords:


    Project Supported:
    This work was supported by the National Natural Science Foundation of China (No. 82174112).

    Clc Number:

WeChat

Mobile website